sefa ozel/E+ via Getty Images
Thorne HealthTech (NASDAQ:THRN) rose 11% on Wednesday.
Last month, the provider of at-home health tests and nutritional supplements was said to be exploring a sale, Reuters reported, citing people familiar with the matter.
Earlier this month, Thorne HealthTech (THRN) reported EPS of $0.15 and sales up 33% to $72.7M.
The company forecast full-year sales of $285M to $290M and gross profit as a percentage of net sales of 50% to 52%. Adjusted EPS is expected to total between $0.26 to $0.32.
“We expect continued momentum across our business as we enter the second half of the year,” Chief Executive Officer Paul Jacobson said on an earnings call.
“This momentum is driven by the launch of additional innovative products and expansion to our sales force that is producing more business wins, the growing international presence and increasing brand awareness of the Thorne name.”
Shares have four Strong Buy ratings from Wall Street analysts.
THRN competes with Hims & Hers Health Inc (HIMS) and 23andMe Holding Co (ME).
The stock is up 119% in 2023.
More on Thorne HealthTech
#Thorne #HealthTech #trades #higher #extending #monthlong #gains #NASDAQTHRN
